Potential savings in the cost of caring for Alzheimer's disease: Treatment with rivastigmine

PharmacoEconomics

Volumn 17, Issue 4, 2000, Pages 351-360

  Hauber, A Brett ^a   Gnanasakthy, Ari ^b   Snyder, Edward H ^b   Bala, Mohan V ^c   Richter, Anke ^a   Mauskopf, Josephine A ^a  

^a RTI INTERNATIONAL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIVASTIGMINE;

AGED; AGING; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; COST CONTROL; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0034058425     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200017040-00005     Document Type: Article

References (15)

1. 1. Corey-Bloom J, Anand R, Veach J, for the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998; 1: 55-65
2. 2. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268: 2523-9
3. 3. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271: 985-91
4. 4. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7: 293-303
5. 5. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-45
6. 6. Rosler M, Anand R, Cicin-Sain A, et al., ENA 713 B303 Study Group. Safety and efficacy of rivastigmine in patients with Alzheimer's disease: results of an international, 26-week, multicentre, randomised, placebo-controlled trial. BMJ 1999; 318: 633-8
7. 7. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98
8. 8. Fenn P, Gray A. Estimating the long term cost savings from the treatment of Alzheimer's disease: a modelling approach. Pharmacoeconomics 1999; 16 (2): 165-74
9. 9. Ernst RL, Hay JW, Fenn C, et al. Cognitive function and the costs of Alzheimer's disease: an exploratory study. Arch Neurol 1997; 54: 687-93
10. 10. Uhlmann RF, Larson EB, Koepsell TD. Hearing impairment and cognitive decline in senile dementia of the Alzheimer's type. J Am Geriatr Soc 1986; 34: 207-10
11. 11. Becker JT, Huff FJ, Nebes RD, et al. Neuropsychological function in Alzheimer's disease: pattern of impairment and rates of progression. Arch Neurol 1988; 45: 263-8
12. 12. Yesavage JA, Poulsen AB, Sheikh J, et al. Rates of change of common measures of impairment in senile dementia of the Alzheimer type. Psychopharmacol Bull 1988; 24: 531-4
13. 13. Salmon DP, Thal LJ, Butters N, et al. Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. Neurology 1990; 40: 1225-30
14. 14. Teri L, Hughes JP, Larson EB. Cognitive deterioration in Alzheimer's disease: behavioral and health factors. J Gerontol B Psychol Sci Soc Sci 1990; 45 (2): 58-63
15. 15. Burns A, Jacoby R, Levy R. Progression of cognitive impairment in Alzheimer's disease. J Am Geriatr Soc 1991; 39: 34-45